AFNT-211: A Phase 1 Study of Autologous CD4+and CD8+T Cells Engineered to Express a High Avidity HLA-A*11:01-restricted, KRAS G12V-specific, Transgenic TCR, a CD8α/β Coreceptor, and a FAS41BB Switch Receptor in Patients with Advanced/metastatic Solid Tumors
JOURNAL OF CLINICAL ONCOLOGY（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined